The drug, called medetomidine, is used by veterinarians to sedate pets. It’s similar to xylazine, another animal drug that has already made the US opioid crisis worse, The Associated Press reported.

Increase seen in lifetime use among adults and adolescents; past-year use higher among young adults, older adults.

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

The phase 3 trial enrolled 1033 patients who had not received prior chemotherapy for mCRPC and had evidence of disease progression despite androgen deprivation therapy.

Rinvoq approved for giant cell arteritis; telehealth companies collaborate with Novo Nordisk for Wegovy access; epidermolysis bullosa wound healing treatment approved; Imaavy approved for gMG; new ...

HealthDay News — Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study published online March 17 in ...

Self-paying patients will now be able to access NovoCare Pharmacy directly through the telehealth platform. Novo Nordisk is collaborating with multiple telehealth organizations in an effort to ...

The review extension was needed as the FDA required time to review Cytokinetics’ proposed Risk Evaluation and Mitigation Strategy (REMS).

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Tepylute is indicated for the treatment of adenocarcinoma of the breast or ovary . It is now supplied as a multiple-dose vial containing 100mg of thiotepa, in addition to the previously approved ...